Skip to main content

Table 2 Cumulative adverse events during treatment by maximum grade per patient during treatment

From: Concurrent chemoradiotherapy with or without cetuximab for stage II to IVb nasopharyngeal carcinoma: a case–control study

  Toxic effects, No. (%) P value*
CCRT alone (n = 124) CCRT + cetuximab(n = 62)
Grade 1 Grade 2 Grade 1 Grade 2 Grade 1–2
Neutropenia 34 (27.4%) 49 (39.5%) 16 (25.8%) 18 (29.0%) 0.107
Leucopenia 36 (29.0%) 24 (19.4%) 17 (27.4%) 13 (21.0%) 1
Anemia 44 (35.5%) 23 (18.5%) 3 (4.8%) 5 (8.1%) < 0.001
Thrombocytopenia 19 (15.3%) 10 (8.1%) 5 (8.1%) 3 (4.8%) 0.091
AST increased 17 (13.7%) 3 (2.4%) 9 (14.5%) 1 (1.6%) 1
ALT increased 22 (17.7%) 11 (8.9%) 31 (50.0%) 4 (6.5%) < 0.001
BUN 9 (7.3%) 1 (0.8%) 2 (3.2%) 1 (1.6%) 0.549
CRE 13 (10.5%) 0 2 (3.2%) 0 0.087
Mucositis 36 (29.0%) 54 (43.5%) 9 (14.5%) 21 (33.9%) 0.001
Dermatitis 73 (58.9%) 26 (21.0%) 28 (45.2%) 23 (37.1%) 0.694
Vomiting 47 (37.9%) 17 (13.7%) 35 (56.5%) 11 (17.7%) 0.003
Weight loss 42 (36.8%) 56 (49.1%) 14 (23.7%) 39 (66.1%) 0.298
Acneiform rash 0 (0.0%) 0 (0.0%) 31 (50.0%) 15 (24.2%) -
  Toxic effects, No. (%) P value*
CCRT alone (n = 124) CCRT + cetuximab(n = 62)
Grade 3 Grade 4 Grade 3 Grade 4
Neutropenia 18 (14.5%) 1 (0.8%) 8 (12.9) 0 (0.0%) 0.097
Leucopenia 8 (6.5%) 1 (0.8%) 4 (6.5%) 0 (0.0%) 1
Anemia 2 (1.6%) 0 (0.0%) 2 (3.2%) 0 (0.0%) 0.602
Thrombocytopenia 4 (3.2%) 1 (0.8%) 1 (1.6%) 0 (0.0%) 0.665
AST increased 0 0 0 0 -
ALT increased 2 (1.6%) 0 1 (1.6%) 0 1
Renal impairment 0 0 0 0 -
BUN 0 0 0 0 -
CRE 0 0 0 0 -
Mucositis 29 (23.4%) 0 (0.0%) 29 (46.8%) 3 (4.8%) < 0.001
Dermatitis 5 (4.0%) 0 (0.0%) 3 (4.8%) 0 (0.0%) 1
Vomiting 2 (1.6%) 0 (0.0%) 2 (3.2%) 1 (1.6%) 0.335
Weight loss 0 - a 2 (3.2%) - a 0.110
  1. Data are n or n (%). *P values were calculated with the χ2 test (or Fisher’s exact test). aAccording to the Common Terminology Criteria for Adverse Events (version 4.0), weight loss has only grade 1–3
  2. Abbreviations: CCRT concurrent chemoradiotherapy, AST aspartate aminotransferase, ALT alanine aminotransferase, BUN blood urea nitrogen, CRE creatinine